Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update
- Positive 12-month Phase 1/2 clinical data in adult cohort and early pediatric clinical data support potential for meaningful vision restoration with OPGx-LCA5 - - FDA grants Regenerative Medicine Advanced Therapy ( RMAT ) designation for OPGx-LCA5 -
Missed Opt-Out Deadline Could Cost Investors Millions In Perrigo Fraud Suit - Perrigo ( NYSE:PRGO )
Perrigo restated over $1 billion in financial misstatements from 2015-2017. Shares plunged more than 62% after accounting and earnings disclosures. The next 100%+ earnings move could hit this month. See how to find it live on Wednesday →
Theravance's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y
TBPH posts better-than-expected second-quarter 2025 results, boosted by Yupelri sales and licensing gains.
Theravance Sales Jump 83 Percent
Theravance Biopharma ( NASDAQ:TBPH ) , a biopharmaceutical company focused on respiratory medicines and rare disease therapeutics, reported its Q2 2025 results on August 12, 2025. The company's revenue ( GAAP ) grew to $26.2 million, slightly ahead of analyst estimates at $25.93 million.
Why Is Amphastar Pharma Stock Soaring Tuesday? - Amphastar Pharma ( NASDAQ:AMPH ) , Fresenius Medical Care ( NYSE:FMS )
FDA approves Amphastar's generic Venofer, eyeing $80 million-$100 million in sales. Amphastar shares were boosted by an analyst upgrade to buy with a $36 target. This simple system has nailed 1,000+ post-earnings winners. Get in before Q3 trades take off → On Monday, the U.S.
Viatris Stock Rises as Q2 Earnings & Revenues Beat Estimates
VTRS beats on Q2 estimates with strength in branded drugs and growth in Greater China, lifting shares.
Viatris ( VTRS ) Tops Q2 Earnings and Revenue Estimates
Viatris (VTRS) delivered earnings and revenue surprises of +10.71% and +2.40%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Lexicon ( LXRX ) Q2 Revenue Soars 1,706%
Lexicon Pharmaceuticals ( NASDAQ:LXRX ) , a biopharma company focused on developing treatments for diabetes, cardiovascular, and neurological diseases, released its second quarter 2025 financial results on August 6, 2025. The most important news: revenue ( GAAP ) reached $28.9 million in the ...
Viatris ( VTRS ) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Get a deeper insight into the potential performance of Viatris (VTRS) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Viatris Poised to Report Q2 Earnings: What's in Store for the Stock?
VTRS braces for Q2 results as branded drug growth in Europe and China offsets generic headwinds in North America.
Strong sales acceleration of QUVIVIQ drives Idorsia toward profitability - H1 2025 results
Ad hoc announcement pursuant to Art. 53 LR ...
Judge Rules Mylan Did Not Infringe Novo Nordisk Patent In Wegovy Generic Case - Novo Nordisk ( NYSE:NVO )
Court grants Mylan judgment of no direct, contributory or induced infringement on U.S. Patent. Mylan's proposed drug label did not instruct use without other therapeutic agents, undermining Novo's case. Up Next: Get 5 Dark Horse Stocks Wall Street Is Quietly Loading Up On
Aquestive Therapeutics Names Sherry Korczynski as Chief Commercial Officer
WARREN, N.J., July 22, 2025 ( GLOBE NEWSWIRE ) -- Aquestive Therapeutics, Inc. ( NASDAQ: AQST ) ( "Aquestive" or the "Company" ) , a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced ...
Aquestive Therapeutics Names Sherry Korczynski as Chief Commercial Officer - Aquestive Therapeutics ( NASDAQ:AQST )
WARREN, N.J., July 22, 2025 ( GLOBE NEWSWIRE ) -- Aquestive Therapeutics, Inc.
VTRS Down on Late-Stage Study Failure of Eye Disease Drug
VTRS slides after phase III trial failure for blepharitis drug MR-139, adding pressure to an already struggling stock.
Viatris Hits Snag In Eye Drug Study-Phase 3 Plans Under Review - Viatris ( NASDAQ:VTRS )
Viatris' pimecrolimus ophthalmic ointment failed to meet the primary endpoint in a Phase 3 blepharitis study. The company may revise its Phase 3 plans after the trial showed no full resolution of eyelid debris after six weeks.
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Geron Corporation, Viatris, Everus Construction, and SoundHound - Everus Construction Group ( NYSE:ECG ) , Geron ( NASDAQ:GERN )
SAN DIEGO, July 18, 2025 ( GLOBE NEWSWIRE ) -- Johnson Fistel, PLLP, is investigating potential violations of federal and state securities laws by certain officers and directors of Geron Corporation GERN, Viatris Inc. VTRS, Everus Construction Group, Inc. ECG, and SoundHound AI, Inc.
Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics
CPRX, ZVRA, TBPH, ALDX, and LRMR shine amid tariff threats, thanks to strong pipelines, demand, and rising earnings estimates.
5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats
Innovation is at its peak in the Zacks Medical-Drugs industry. CPRX, ZVRA, TBPH, ALDX and LRMR may prove to be good additions to one's portfolio.
Viatris Eye Drops Data Shows Promise For Blurred Near Vision - Viatris ( NASDAQ:VTRS ) , Opus Genetics ( NASDAQ:IRD )
MR-141 met primary endpoint with ≥3-line near vision gain at 12 hours post-dose on Day 8 vs. placebo ( p<0.0001 ) . No serious adverse events; most common side effects were mild, including eye redness and site irritation. Market-moving news hits Benzinga Pro first-get a 30-minute edge and ...
Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
• Study met its primary and key secondary endpoints, demonstrating rapid and sustained improvement in near visual acuity • Safety profile consistent with previous clinical trials and no treatment-related serious adverse events reported in the study • No evidence of tachyphylaxis was observed in ...
Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia - Opus Genetics ( NASDAQ:IRD )
Study met its primary and key secondary endpoints, demonstrating rapid and sustained improvement in near visual acuity Safety profile consistent with previous clinical trials and no treatment-related serious adverse events reported in the study
Kuehn Law Encourages Investors of Viatris Inc. to Contact Law Firm - Viatris ( NASDAQ:VTRS )
NEW YORK, June 10, 2025 ( GLOBE NEWSWIRE ) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Viatris Inc. VTRS breached their fiduciary duties to shareholders.
Zacks Industry Outlook Highlights Sandoz, Teva Pharmaceuticals and Viatris
SDZNY, TEVA, and VTRS show resilience with strong biosimilar pipelines and margin strategies amid industry headwinds.
3 Generic Drug Stocks to Watch Amid Pricing Pressure & Tariff Threats
Sandoz, Teva and Viatris are navigating generic drug pricing pressure with scale, complex generics and cost cuts.
Goldman Sachs Bullish On Branded Drug Upside At Teva: What About Viatris? - Viatris ( NASDAQ:VTRS ) , Teva Pharmaceutical Indus ( NYSE:TEVA ) , Amneal Pharmaceuticals ( NASDAQ:AMRX )
Goldman Sachs sets $24 price target on Teva, citing branded growth and biosimilar pipeline. Amneal gets Buy rating with $12 target as Goldman lauds Parkinson's launch and generics focus. Ready to turn the market's comeback into steady cash flow? Grab the top 3 stocks to buy right here.
TBPH to Sell Remaining Trelegy Royalty Interest to GSK, Stock Rises
Theravance to sell its remaining Trelegy royalty interest to GSK for $225M, with shares jumping 22% on the deal's announcement.
DEADLINE ALERT for VTRS and CGC: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders - Viatris ( NASDAQ:VTRS ) , Canopy Gwth ( NASDAQ:CGC )
LOS ANGELES, June 03, 2025 ( GLOBE NEWSWIRE ) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Viatris Inc. of Class Action Lawsuit and Upcoming Deadlines - VTRS - Viatris ( NASDAQ:VTRS )
NEW YORK, June 02, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP announces that a class action lawsuit has been filed against Viatris, Inc. ( "Viatris" or the "Company" ) VTRS. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ( or 888.4-POMLAW ) , ...
VTRS STOCK DEADLINE TOMORROW: Suffer Losses on Viatris Inc.? BFA Law Notifies Investors of Imminent June 3 Securities Class Action Deadline ( NASDAQ:VTRS ) - Viatris ( NASDAQ:VTRS )
NEW YORK, June 02, 2025 ( GLOBE NEWSWIRE ) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Viatris Inc. VTRS and certain of the Company's senior executives for potential violations of the federal securities laws.
Novo Nordisk faces fierce competition in China's diabetes drug market
Competition in the mainland Chinese market for diabetes and weight loss drugs is set to intensify as more than 60 late-stage drug candidates are undergoing clinical trials, according to a recent report. Up to 20 biosimilar or generic copies will vie for market share and add pricing pressure after ...
VTRS DEADLINE ALERT: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Viatris Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 3 Deadline in Securities Class Action - VTRS - Viatris ( NASDAQ:VTRS )
NEW YORK, June 01, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Viatris Inc. VTRS between August 8, 2024 and February 26, 2025, both dates inclusive ( the "Class Period" ) , of the important June 3, 2025 lead plaintiff ...
VTRS CLASS NOTICE: Viatris Inc. Investors may have been Affected by Fraud - Contact BFA Law before June 3 Court Deadline ( NASDAQ:VTRS ) - Viatris ( NASDAQ:VTRS )
NEW YORK, May 31, 2025 ( GLOBE NEWSWIRE ) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Viatris Inc. VTRS and certain of the Company's senior executives for potential violations of the federal securities laws.
SHAREHOLDER REMINDER: Berger Montague Reminds Viatris ( NASDAQ: VTRS ) Investors of the June 3, 2025 Deadline - Viatris ( NASDAQ:VTRS )
PHILADELPHIA, May 30, 2025 ( GLOBE NEWSWIRE ) -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Viatris Inc. ( "Viatris" or the "Company" ) VTRS on behalf of purchasers of Viatris securities between August 8, 2024 through February 26, 2025, ...
VTRS DEADLINE: ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Viatris Inc. Investors to Secure Counsel Before Important June 3 Deadline in Securities Class Action - VTRS - Viatris ( NASDAQ:VTRS )
NEW YORK, May 29, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Viatris Inc. VTRS between August 8, 2024 and February 26, 2025, both dates inclusive ( the "Class Period" ) , of the important June 3, 2025 lead plaintiff ...
The Gross Law Firm Notifies Shareholders of Viatris Inc. ( VTRS ) of a Class Action Lawsuit and an Upcoming Deadline - Viatris ( NASDAQ:VTRS )
NEW YORK, May 29, 2025 ( GLOBE NEWSWIRE ) -- The Gross Law Firm issues the following notice to shareholders of Viatris Inc. VTRS. Shareholders who purchased shares of VTRS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Viatris Inc. ( VTRS ) Lawsuit - Investors Urged to Contact Levi & Korsinsky Before June 3, 2025
Viatris Inc. (VTRS) Lawsuit - Investors Urged to Contact Levi & Korsinsky Before June ...
DEADLINE ALERT for VTRS, CGC, and ECG: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders - Everus Construction Group ( NYSE:ECG ) , Canopy Gwth ( NASDAQ:CGC )
LOS ANGELES, May 28, 2025 ( GLOBE NEWSWIRE ) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.
VTRS Investors Have the Opportunity to Lead the Viatris Securities Fraud Lawsuit with Faruqi & Faruqi, LLP - Viatris ( NASDAQ:VTRS )
Faruqi & Faruqi, LLP Securities Litigation Partner James ( Josh ) Wilson Encourages Investors Who Suffered Significant Losses In Viatris To Contact Him Directly To Discuss Their Options
VIATRIS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Viatris Inc. - VTRS - Viatris ( NASDAQ:VTRS )
NEW YORK and NEW ORLEANS, May 27, 2025 ( GLOBE NEWSWIRE ) -- Kahn Swick & Foti, LLC ( "KSF" ) and KSF partner, former Attorney General of Louisiana, Charles C.
Viatris Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. June 3, 2025 Deadline to file Lead Plaintiff Motion - Viatris ( NASDAQ:VTRS )
LOS ANGELES, May 27, 2025 ( GLOBE NEWSWIRE ) -- The Portnoy Law Firm advises Viatris Inc. ( "Viatris" or the "Company" ) VTRS investors of a class action representing investors that bought securities between August 8, 2024 and February 26, 2025, inclusive ( the "Class Period" ) .
DEADLINE NEXT WEEK: Berger Montague Advises Viatris ( NASDAQ: VTRS ) Investors to Contact the Firm Before June 3, 2025 - Viatris ( NASDAQ:VTRS )
PHILADELPHIA, May 27, 2025 ( GLOBE NEWSWIRE ) -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Viatris Inc. ( "Viatris" or the "Company" ) VTRS on behalf of purchasers of Viatris securities between August 8, 2024 through February 26, 2025, ...
Contact Levi & Korsinsky by June 3, 2025 to Join Class Action Against Viatris Inc. ( VTRS )
Contact Levi & Korsinsky by June 3, 2025 to Join Class Action Against Viatris Inc. ...
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ...
VTRS FRAUD NOTICE: Viatris Inc. Investors with Losses are Reminded to Contact BFA Law about the Pending Securities Fraud Class Action
New York, New York-- ( Newsfile Corp. - May 24, 2025 ) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Viatris Inc. ( NASDAQ: VTRS ) and certain of the Company's senior executives for potential violations of the federal securities laws.
VTRS IMPORTANT DEADLINE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Viatris Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 3 Deadline in Securities Class Action - VTRS - Viatris ( NASDAQ:VTRS )
NEW YORK, May 23, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Viatris Inc. VTRS between August 8, 2024 and February 26, 2025, both dates inclusive ( the "Class Period" ) , of the important June 3, 2025 lead plaintiff ...
Viatris ( NASDAQ: VTRS ) Deadline Approaching: Berger Montague Advises Investors of Deadline in Securities Fraud Lawsuit - Viatris ( NASDAQ:VTRS )
PHILADELPHIA, May 23, 2025 ( GLOBE NEWSWIRE ) -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Viatris Inc. ( "Viatris" or the "Company" ) VTRS on behalf of purchasers of Viatris securities between August 8, 2024 through February 26, 2025, ...
VTRS FRAUD ALERT: Lose Money when Viatris Inc. Stock Dropped 15%? Contact BFA Law by June 3 Class Action Deadline ( NASDAQ:VTRS ) - Viatris ( NASDAQ:VTRS )
NEW YORK, May 23, 2025 ( GLOBE NEWSWIRE ) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Viatris Inc. VTRS and certain of the Company's senior executives for potential violations of the federal securities laws.
Peering Into Viatris's Recent Short Interest - Viatris ( NASDAQ:VTRS )
Viatris's VTRS short percent of float has risen 7.99% since its last report. The company recently reported that it has 48.71 million shares sold short, which is 4.73% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.51 days to cover their ...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Canopy Growth, Viatris, Bakkt, and Cerevel and Encourages Investors to Contact the Firm - Bakkt Hldgs ( NYSE:BKKT ) , Canopy Gwth ( NASDAQ:CGC )
NEW YORK, May 21, 2025 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Canopy Growth Corporation CGC, Viatris Inc. VTRS, Bakkt Holdings, Inc.
